rpcardioRational Pharmacotherapy in CardiologyРациональная Фармакотерапия в Кардиологии1819-64462225-3653«SILICEA-POLIGRAF» LLC10.20996/1819-6446-2022-03-01rpcardio-2717Research ArticleCURRENT QUESTIONS OF CLINICAL PHARMACOLOGYАКТУАЛЬНЫЕ ВОПРОСЫ КЛИНИЧЕСКОЙ ФАРМАКОЛОГИИAntiarrhythmic and Hemodynamic Effects of Omega-3 Polyunsaturated Fatty Acids on Cardiovascular DiseasesАнтиаритмические и гемодинамические эффекты омега-3 полиненасыщенных жирных кислот при сердечно-сосудистых заболеванияхhttps://orcid.org/0000-0001-7886-2549ЗакироваА. Н.ZakirovaA. N.

Закирова Аляра Нурмухаметовна

Уфа

Alyara N. Zakirova

Ufa

zinfira.67@mail.ruhttps://orcid.org/0000-0002-5462-4885ЗакироваН. Н.ZakirovaN. E.

Закирова Нэлли Эриковна

Уфа

Nelli E. Zakirova

Ufa

Башкирский государственный медицинский университетРоссияBashkir State Medical UniversityRussian Federation202206052022182209217Copyright © Zakirova A.N., Zakirova N.E., 20222022Закирова А.Н., Закирова Н.Н.Zakirova A.N., Zakirova N.E.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.rpcardio.online/jour/article/view/2717

This review presents the results of previously performed epidemiological, experimental and clinical studies indicating the use of ω-3 PUFA (polyunsaturated fatty acids) contributes to reduce the risk of developing cardiovascular diseases. Experimental studies have shown ω-3 PUFA are exhibiting antiarrhythmic effects, improving endothelial function, showing an anti- inflammatory effect, affecting the rheological properties of blood, reducing triglyceride concentrations, and increasing the stability of atheromatous plaque. Wide-scale clinical trials have established high efficacy of ω-3 PUFA in primary and secondary prevention of coronary heart disease. It is found to reduce the risk of ventricular arrhythmias and sudden cardiac death. Also, reduces overall mortality and hospitalization rates due to cardiovascular causes in patients with chronic heart failure. Clinical efficacy among cardiovascular diseases of the prescription drugs ω-3 PUFA standardized by qualitative and quantitative compositions to be studied further in a comparison to the other medications with similar make-up.

В обзоре представлены результаты ранее выполненных эпидемиологических, экспериментальных и клинических исследований, свидетельствующих о том, что применение омега-3 полиненасыщенных жирных кислот (ω-3 ПНЖК) способствует снижению риска развития сердечно-сосудистых заболеваний (ССЗ). В экспериментальных работах показано, что ω-3 ПНЖК проявляют антиаритмические эффекты, улучшают функцию эндотелия, оказывают противовоспалительное действие, влияют на реологические свойства крови, снижают концентрацию триглицеридов и повышают стабильность атероматозной бляшки. В крупномасштабных клинических исследованиях установлена высокая эффективность применения ω-3 ПНЖК в первичной и вторичной профилактике ишемической болезни сердца, для снижения риска желудочковых аритмий и внезапной сердечной смерти, уменьшения общей смертности и частоты госпитализации в связи с сердечно-сосудистыми причинами у пациентов с хронической сердечной недостаточностью. Представляется перспективным дальнейшее изучение при ССЗ клинической эффективности стандартизированных по качеству и количественному составу рецептурных препаратов ω-3 ПНЖК по сравнению с другими их источниками.

омега-3 полиненасыщенные жирные кислотысердечно-сосудистые заболеванияишемическая болезнь сердцанарушения ритма сердцахроническая сердечная недостаточностьω-3 polyunsaturated fatty acidscardiovascular diseasesischemic heart diseasecardiac arrhythmiaschronic heart failureПубликация статьи поддержана компанией Эбботт Лэбораториз, что не повлияло на собственное мнение авторов.The publication of the article is supported by Abbott Laboratories, but it did not affect own opinion of the authors.ReferencesРоссия в цифрах 2019. Краткий статистический сборник. М.: Росстат; 2019.Russia in numbers 2019. Brief statistical collection. Moscow: Rosstat; 2019 (In Russ.) [Россия в цифрах 2019. Краткий статистический сборник. М.: Росстат; 2019].Szummer K, Wallentin L, Lindhagen L, et al. Improved outcomes in patients with ST-elevation myocardial infarction during the last 20 years are related to implementation of evidence-based treat-ments: experiences from the SWEDEHEART registry 1995-2014. Eur Heart J. 2017;38(41):3056-65. DOI:10.1093/eurheartj/ehx 515.Szummer K, Wallentin L, Lindhagen L, et al. Improved outcomes in patients with ST-elevation myocardial infarction during the last 20 years are related to implementation of evidence-based treat-ments: experiences from the SWEDEHEART registry 1995-2014. Eur Heart J. 2017;38(41):3056-65. DOI:10.1093/eurheartj/ehx 515.Гиляревский С.Р. Эффективность применения омега-3 полиненасыщенных жирных кислот для первичной и вторичной профилактики сердечно-сосудистых заболеваний: современное состояние проблемы. Фарматека. 2010;(20):11-9.Gilyarevsky SR. The effectiveness of the use of omega-3 polyunsaturated fatty acids for primary and secondary prevention of cardiovascular diseases: the current state of the problem. Pharmateca 2010;(20):11- 9 (In Russ.)Говорин А.В., Филев А.П. Омега-3 полиненасыщенные жирные кислоты в лечении больных с сер-дечно-сосудистыми заболеваниями. Рациональная Фармакотерапия в Кардиологии. 2012;8(1):95-102. DOI:10.20996/1819-6446-2012-8-1-95-102.Govorin AV, Filev AP. Omega-3 polyunsaturated fatty acids in the treatment of patients with car-diovascular diseases. Rational Pharmacotherapy in Cardiology. 2012:8(1):95-102 (In Russ.) DOI:10.20996/1819-6446-2012-8-1-95-102.Подзолков В.И., Тарзиманова А.И. Значение омега-3 полиненасыщенных жирных кислот в профилактике нарушений сердечного ритма. Рациональная Фармакотерапия в Кардиологии. 2020;16(3):498-502. DOI:10.20996/1819-6446-2020-05-01.Podzolkov VI, Tarzimanova AI. The value of omega-3 polyunsaturated fatty acids in the preven-tion of cardiac arrhythmias. Rational Pharmacotherapy in Cardiology. 2020;16(3):498-502 (In Russ.) DOI:10.20996/1819-6446-2020-05-01.Подзолков В.И., Писарев М.В. Роль омега-3 полиненасыщенных жирных кислот в управлении сердечно-сосудистым риском. Кардиоваскулярная Терапия и Профилактика. 2020;19(3):86-94. DOI:10.15829/1728-8800-2020-2589.Podzolkov VI, Pisarev MV. The role of omega-3 polyunsaturated fatty acids in the management of cardiovascular risk. Cardiovascular Therapy and Prevention. 2020;19(3):86-94 (In Russ.) DOI:10.15829/1728-8800-2020-2589.Сусеков А.В. Омега-3 полиненасыщенные жирные кислоты у больных с гипертриглицеридемиями и атеросклерозом. Кардиология. 2021;61(6):88-96 DOI:10.18087/cardio 2021.6. n 1578.Susekov AV. Omega-3 polyunsaturated fatty acids in patients with hypertriglyceridemia and ather-osclerosis. Kardiologiia. 2021;61(6):88-96 (In Russ.)Lee JH, O'Keefe H, Lavie C, et al. Omega-3 fatty acids for cardioprotection. Mayo Clin Proc. 2008;83(3):324-32. DOI:10.4065/83.3.324.Lee JH, O'Keefe H, Lavie C, et al. Omega-3 fatty acids for cardioprotection. Mayo Clin Proc. 2008;83(3):324-32. DOI:10.4065/83.3.324.Newman WP, Middaugh JA, Roger DR. Atherosclerosis in Alaska Natives and non-natives. The Lancet. 1993;341(8852):1056-7. DOI:10.1016/0140 – 6736(93) 92413-N.Newman WP, Middaugh JA, Roger DR. Atherosclerosis in Alaska Natives and non-natives. The Lancet. 1993;341(8852):1056-7. DOI:10.1016/0140 – 6736(93) 92413-N.Kromann N, Green A. Epidemiological studies is the Upernavik district, Greenland. Incidence of some chronic diseases 1950-1974. Acta Med Scand. 1980;208(5):401-6. DOI:10.1111/j.0954-6820.1980.tb01221.x.Kromann N, Green A. Epidemiological studies is the Upernavik district, Greenland. Incidence of some chronic diseases 1950-1974. Acta Med Scand. 1980;208(5):401-6. DOI:10.1111/j.0954-6820.1980.tb01221.x.Bang HO, Dyerberg J. Lipid metabolism and ischemic heart disease in Greenland Eskimos. In: Draper H., ed. Advances in Nutrition Research. New York, NY: Plenum Press; 1980. P. 1-22. DOI:10.1007/978-1-4757-4448-4_1.Bang HO, Dyerberg J. Lipid metabolism and ischemic heart disease in Greenland Eskimos. In: Draper H., ed. Advances in Nutrition Research. New York, NY: Plenum Press; 1980. P. 1-22. DOI:10.1007/978-1-4757-4448-4_1.Middaugh JP. Cardiovascular deaths among Alaskan Natives, 1980-1986. Am J Public Health. 1990;80(3):282-5. DOI:10.2105/AJPH.80.3.282.Middaugh JP. Cardiovascular deaths among Alaskan Natives, 1980-1986. Am J Public Health. 1990;80(3):282-5. DOI:10.2105/AJPH.80.3.282.Аронов Д.M. Место омега-3 полиненасыщенных жирных кислот в лечении атеросклероза и ИБС. Русский Медицинский Журнал. 2006;20(272):1418-22.Aronov DM. The place of omega-3 polyunsaturated fatty acids in the treatment of atherosclerosis and coronary heart disease. Russian Medical Journal. 2006;20(272):1418-22 (In Russ.)Mozaffarian D, Wu JH. Omega-3 fatty acids and cardiovascular disease: effects on risk factors, molecular pathways, and clinical events. J Am Coll Cardiol. 2011;58(20):2047-67. DOI:10.1016/j.jacc.2011. 06.063.Mozaffarian D, Wu JH. Omega-3 fatty acids and cardiovascular disease: effects on risk factors, molecular pathways, and clinical events. J Am Coll Cardiol. 2011;58(20):2047-67. DOI:10.1016/j.jacc.2011.06.063.Сулимов В., Коппато Р., Халкокс Ю. и др. Применение N-3 Полиненасыщенных жирных кислот 90% (Омакор) для лечения и профилактики сердечно-сосудистых заболеваний. Рациональная Фармакотерапия в Кардиологии 2011;7(1):103-6.Sulimov V, Kоppato Р, Halcox U, et al. The use of N-3 Polyunsaturated fatty acids 90% (Oma-cor) for the treatment and prevention of cardiovascular diseases. Rational Pharmacotherapy in Cardi-ology. 2011;7(1):103-6 (In Russ.)De Wintber MPJ, Kanters E, Kraal G, et al. Nuclear Factor kB Signaling in Atherogenesis. Arterioscler Thromb Vasc Biol. 2005;25(5):904-14. DOI:10.1161/01.ATV.0000160340.72641.87.De Wintber MPJ, Kanters E, Kraal G, et al. Nuclear Factor kB Signaling in Atherogenesis. Arte-rioscler Thromb Vasc Biol. 2005;25(5):904-14. DOI:10.1161/01.ATV.0000160340.72641.87.Mason RP, Libby P, Bhatt DL. Emerging Mechanisms of Cardiovascular Protection for the Ome-ga-3 Fatty Acid. Eicosapentaenoic Acid. Arterioscler Thromb Vasc Biol. 2020;40(5):1135-47. DOI:10.1161/ATVBAHA.119.313286.Mason RP, Libby P, Bhatt DL. Emerging Mechanisms of Cardiovascular Protection for the Ome-ga-3 Fatty Acid. Eicosapentaenoic Acid. Arterioscler Thromb Vasc Biol. 2020;40(5):1135-47. DOI:10.1161/ATVBAHA.119.313286.Кисляк О.А., Стародубова А.В. Современные взгляды на возможности применения этиловых эфиров w-3 – полиненасыщенных жирных кислот 90% в лечении и профилактике сердечно-сосудистых заболеваний и ХСН. Атмосфера. Новости кардиологии. 2011;(3):28-32.Kislyak OA, Starodubova AV. Modern views on the possibilities of using ethyl esters of w-3 - polyunsaturated fatty acids 90% in the treatment and prevention of cardiovascular diseases and CHF. Atmosphere. Cardiology News. 2011;(3):28-32 (In Russ.)Li G, Sun H, Zhang X, et al. Omega-3 polyunsaturated fatty acids inhibit transient outward and ultrapid delayed rectifier K+ currents and Na+ current in human atrial myocytes. Cardiovasc Res. 2009;81(2):286-93. DOI:10.1093/cvr/cvn 322.Li G, Sun H, Zhang X, et al. Omega-3 polyunsaturated fatty acids inhibit transient outward and ultrapid delayed rectifier K+ currents and Na+ current in human atrial myocytes. Cardiovasc Res. 2009;81(2):286-93. DOI:10.1093/cvr/cvn 322.Kromhout D, Yasuda S, Geleijnse JM, Shimokawa H. Fish oil and omega-3 fatty acids in cardiovascular disease: do they really work? Eur Heart J. 2012;33(4):436-43. DOI:101093/eurheartj/ehr 362.Kromhout D, Yasuda S, Geleijnse JM, Shimokawa H. Fish oil and omega-3 fatty acids in cardi-ovascular disease: do they really work? Eur Heart J. 2012;33(4):436-43. DOI:101093/eurheartj/ehr 362.Harris WS, Poston WC, Haddock CK. Tissue n-3 and n-6 fatty acids and for coronary heart disease events. Atherosclerosis. 2007;193(1):1-10. DOI:10.1016/j.atherosclerosis.2007.03.018.Harris WS, Poston WC, Haddock CK. Tissue n-3 and n-6 fatty acids and for coronary heart dis-ease events. Atherosclerosis. 2007;193(1):1-10. DOI:10.1016/j.atherosclerosis.2007.03.018.Vokoyama M, Origasa H, Matsuzaki M, et al. Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomized open-label, blinded endpoint analysis. The Lancet. 2007;369(9567):1090-8. DOI:10.1016/S0140-6736 (07) 60527-3.Vokoyama M, Origasa H, Matsuzaki M, et al. Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomized open-label, blinded endpoint analysis. The Lancet. 2007;369(9567):1090-8. DOI:10.1016/S0140-6736 (07) 60527-3.Burr ML, Fehily AM, Gilbert JF, et al. Effects of changes in fat, fish, and fibre intakes on death and myocardial reinfarction: Diet and Reinfarction Trial (DART). Lancet. 1989;2(8666):757-61. DOI:10.1016/S0140-6736(89)90828-3.Burr ML, Fehily AM, Gilbert JF, et al. Effects of changes in fat, fish, and fibre intakes on death and myocardial reinfarction: Diet and Reinfarction Trial (DART). Lancet. 1989;2(8666):757-61. DOI:10.1016/S0140-6736(89)90828-3.Dietary Supplementation with n-3 polyunsaturated fatty acids and vitamin Е after myocardial infarction: results of the GISSI-Prevenzione trial. Gruppo Italiano per lo Studio della Sopravvivenza nell Infarto miocardico. Lancet. 1999;354(9177):447-55.Dietary Supplementation with n-3 polyunsaturated fatty acids and vitamin Е after myocardial in-farction: results of the GISSI-Prevenzione trial. Gruppo Italiano per lo Studio della Sopravvivenza nellꞋInfarto miocardico. Lancet. 1999;354(9177):447-55.Marchioli R. Early Protection Against Sudden Death by n-3 Polyunsaturated Fatty Acids After Myocardial Infarction: Time-Course Analysis of the results Gruppa Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico (GISSI) – Prevenzione. Circulation. 2002;105(16):1897-903. DOI:10.1161/01.CIR.0000014682.14181.F2.Marchioli R. Early Protection Against Sudden Death by n-3 Polyunsaturated Fatty Acids After Myocardial Infarction: Time-Course Analysis of the results Gruppa Italiano per lo Studio della So-pravvivenza nell'Infarto Miocardico (GISSI) – Prevenzione. Circulation. 2002;105(16):1897-903. DOI:10.1161/01.CIR.0000014682.14181.F2.GISSI-HF investigators; Tavazzi L, Maggioni AP, Marchioli R, et al. Effect of n-3 polyun-satarated fatty acids in patients with chronic heart failure (The GISSI-HF trial): a randomized, double-blind, placebo-controlled trial. Lancet. 2008;372(9645):1223-30. DOI:10.1016/S0140-6736(08)61239-8.GISSI-HF investigators; Tavazzi L, Maggioni AP, Marchioli R, et al. Effect of n-3 polyun-satarated fatty acids in patients with chronic heart failure (The GISSI-HF trial): a randomized, double-blind, placebo-controlled trial. Lancet. 2008;372(9645):1223-30. DOI:10.1016/S0140-6736(08)61239-8.Bhatt DL, Steg PG, Miller M, et al. Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia. New Engl J Med. 2019;380(1):11-22. DOI:10.1056/NEJMoa1812792.Bhatt DL, Steg PG, Miller M, et al. Cardiovascular Risk Reduction with Icosapent Ethyl for Hy-pertriglyceridemia. New Engl J Med. 2019;380(1):11-22. DOI:10.1056/NEJMoa1812792.Sekikawa A, Cui C, Sugiyama D, et al. Effect of High-Dose Marine Omega-3 Fatty Acids on Atherosclerosis: a Systematic Review and Meta-Analysis of Randomized Clinical Trials. Nutrients. 2019;11(11):2599. DOI:10.3390/nu11112599.Sekikawa A, Cui C, Sugiyama D, et al. Effect of High-Dose Marine Omega-3 Fatty Acids on Atherosclerosis: a Systematic Review and Meta-Analysis of Randomized Clinical Trials. Nutrients. 2019;11(11):2599. DOI:10.3390/nu11112599.ASCEND Study Collaboration Group; Bownan L, Mafham M, Welemaszus K, et al. Effects of n-3 Fatty Acid Supplements in Diabetes Mellitus. N Engl J Med. 2018;379(16):1540-50. DOI:10/1056/NEjMoa1804989.ASCEND Study Collaboration Group; Bownan L, Mafham M, Welemaszus K, et al. Effects of n-3 Fatty Acid Supplements in Diabetes Mellitus. N Engl J Med. 2018;379(16):1540-50. DOI:10/1056/NEjMoa1804989.Manson JE, Cook NR, Lee IM, et al. Marine n-3 Fatty Acids and Prevention of Cardiovascular Disease and Canur. N Engl J Med. 2019;380(1):23-32. DOI:10.1056/ NEjMoa 1811403.Manson JE, Cook NR, Lee IM, et al. Marine n-3 Fatty Acids and Prevention of Cardiovascular Disease and Canur. N Engl J Med. 2019;380(1):23-32. DOI:10.1056/ NEjMoa 1811403.Rauch B, Schiele R, Schneider S, et al. OMEGA, a Randomized, Placebo-Controlled Trial to Test the effect of Highly Purified Omega-3 Fatty Acids on top of Modern Guideline-Adjusted Therapy after myocardial Infaction. Circulation. 2010;122(21):2152-9. DOI:10.1161/CirculatioNAHA.110.948562.Rauch B, Schiele R, Schneider S, et al. OMEGA, a Randomized, Placebo-Controlled Trial to Test the effect of Highly Purified Omega-3 Fatty Acids on top of Modern Guideline-Adjusted Therapy after myocardial Infaction. Circulation. 2010;122(21):2152-9. DOI:10.1161/CirculatioNAHA.110.948562.Nicholls SJ, Lincoff AM, Garcia M, et al. Effect of High-Dose Omega-3 Fatty Acids vs Corn on Major Adverse Cardiovascular Eveats in Patients at High Cardiovascular Risk: The STRENGTH Randomized Clinical Trial. JAMA. 2020;324(22):2268-80. DOI:10.1001/jama.2020.22258.Nicholls SJ, Lincoff AM, Garcia M, et al. Effect of High-Dose Omega-3 Fatty Acids vs Corn on Major Adverse Cardiovascular Eveats in Patients at High Cardiovascular Risk: The STRENGTH Randomized Clinical Trial. JAMA. 2020;324(22):2268-80. DOI:10.1001/jama.2020.22258.Visseren FLJ, Mach F, Smulders VM, et al. ESC Scientific Document Group; ESC National Cardiac Societies. 2021 ESC Guidelines on Cardiovascular disease prevention in clinical practice. Eur Heart J. 2021;42(34):3227-337. DOI:10.1093/eurheartj/ehab 484.Visseren FLJ, Mach F, Smulders VM, et al. ESC Scientific Document Group; ESC National Cardiac Societies. 2021 ESC Guidelines on Cardiovascular disease prevention in clinical practice. Eur Heart J. 2021;42(34):3227-337. DOI:10.1093/eurheartj/ehab 484.Priori SG, Blomtsrom-Lundqvist C. 2015 European Society of Cardiology Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death summarized by cochairs. Eur Heart J. 2015; 36(41):2757-9. DOI:10.1093/eurheartj/ehv445.Priori SG, Blomtsrom-Lundqvist C. 2015 European Society of Cardiology Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death summarized by cochairs. Eur Heart J. 2015; 36(41):2757-9. DOI:10.1093/eurheartj/ehv445.Niemejer MN, van den Berg ME, Leening MJ, et al. Declining incidence of sudden cardiac death from 1990-2010 in a general middle-aged and elderly population: the Rotterdam Study. Heart Rhythm. 2015;12(1):123-9. DOI:10.1016/j.hrthm.2014.09.054.Niemejer MN, van den Berg ME, Leening MJ, et al. Declining incidence of sudden cardiac death from 1990-2010 in a general middle-aged and elderly population: the Rotterdam Study. Heart Rhythm. 2015;12(1):123-9. DOI:10.1016/j.hrthm.2014.09.054.Ander VP, Mc Dupasquier C, Prociuk MA, Pierce GN. Polyunsaturated fatty acids and their effects on cardiovascular disease. Exp Clin Cardiol. 2003;8(4):164-72.Ander VP, Mc Dupasquier C, Prociuk MA, Pierce GN. Polyunsaturated fatty acids and their ef-fects on cardiovascular disease. Exp Clin Cardiol. 2003;8(4):164-72.Leaf A, Xiao Y, Kang J, Billman G. Membrane effects of the n-3 fish oil fatty acids, which prevent fatal ventricular arrhythmias. J Member Biol. 2005;206(2):129-39. DOI:10.1007/s00232-005-0789-9.Leaf A, Xiao Y, Kang J, Billman G. Membrane effects of the n-3 fish oil fatty acids, which pre-vent fatal ventricular arrhythmias. J Member Biol. 2005;206(2):129-39. DOI:10.1007/s00232-005-0789-9.Oh D, Talukdar S, Bae E, et al. GPR 120 is an omega-3 fatty acid receptor mediating potent anti-inflammatory and insulin-sensitizing effects. Cell. 2010;142(5):687-98. DOI:10.1016/j.cell.2010.07.041.Oh D, Talukdar S, Bae E, et al. GPR 120 is an omega-3 fatty acid receptor mediating potent anti-inflammatory and insulin-sensitizing effects. Cell. 2010;142(5):687-98. DOI:10.1016/j.cell.2010.07.041.Li G, Sun H, Zhang X, et al. Omega-3 polyunsaturated fatty acids inhitbit transient outward and ultrarapid delayed rectifier K+ currents and Na+ current in human atrial myocytes. Cardiovsc Res. 2009;81(2):286-93. DOI:10.1093(cvr)cvn322.Li G, Sun H, Zhang X, et al. Omega-3 polyunsaturated fatty acids inhitbit transient outward and ultrarapid delayed rectifier K+ currents and Na+ current in human atrial myocytes. Cardiovsc Res. 2009;81(2):286-93. DOI:10.1093(cvr)cvn322.Nodari S, Triggini M,Campia U, et al. Effects of n-3 polyunsaturated fatty acids on left ventricular function and functional capacity in patients with dilated cardiomyopathy. J Am Coll Cardiol. 2011;57(7):870-9. DOI:10.1016/j.jacc.2010.11.017.Nodari S, Triggini M,Campia U, et al. Effects of n-3 polyunsaturated fatty acids on left ven-tricular function and functional capacity in patients with dilated cardiomyopathy. J Am Coll Cardiol. 2011;57(7):870-9. DOI:10.1016/j.jacc.2010.11.017.Weisman D, Beinart R, Erez A, et al. Effect of supplemented intake of omega-3 fatty acids on arrhythmias in patients with ICD: fish oil therapy may reduced ventricular arrhythmia. J Interv Card Electrophysiol. 2017;49(3):255-61. DOI:10.1007/s 10840-017-0267-1.Weisman D, Beinart R, Erez A, et al. Effect of supplemented intake of omega-3 fatty acids on ar-rhythmias in patients with ICD: fish oil therapy may reduced ventricular arrhythmia. J Interv Card Electrophysiol. 2017;49(3):255-61. DOI:10.1007/s 10840-017-0267-1.Cleland IG, Coletta AP, Lammiman M, et al. Clinical trials update from the European Society of Cardiology meeting 2005: CARE-HF extension study, ESSENTIAL, CIBIS-III, S-ICD, ISSUE-2, STRIDE-2, SOFA, IMAGINE, PREAMI, SIRIUS-II and ACTIVE. Eur J Heart Fail. 2005;7(6):1070-5. DOI:10.1016/j.ejheart.2005.09.006.Cleland IG, Coletta AP, Lammiman M, et al. Clinical trials update from the European Society of Cardiology meeting 2005: CARE-HF extension study, ESSENTIAL, CIBIS-III, S-ICD, ISSUE-2, STRIDE-2, SOFA, IMAGINE, PREAMI, SIRIUS-II and ACTIVE. Eur J Heart Fail. 2005;7(6):1070-5. DOI:10.1016/j.ejheart.2005.09.006.Reffel JA, Mc Donald A. Antiarrhythmic effects of omega-3 fatty acids. Am J Cardiol. 2006;98(4A):50-61. DOI:10.1016/j.amjcard.2005.12.027.Reffel JA, Mc Donald A. Antiarrhythmic effects of omega-3 fatty acids. Am J Cardiol. 2006;98(4A):50-61. DOI:10.1016/j.amjcard.2005.12.027.Harris WS. The omega-3 index as a risk factor for coronary heart disease. Am J Clin Nutr. 2008;87(6):1997S-2003S. DOI:10.1093/ajcn/87.6.1997S.Harris WS. The omega-3 index as a risk factor for coronary heart disease. Am J Clin Nutr. 2008;87(6):1997S-2003S. DOI:10.1093/ajcn/87.6.1997S.Berry J, Possman R, Prinea SR, et al. Fish and omega-3 fatty acid and incident atrial fibrillation: the womenꞋs Health initiative. Am J Cardiol. 2010;105(6):844-8. DOI:10.1016/j.amjcard.2009.11.039.Berry J, Possman R, Prinea SR, et al. Fish and omega-3 fatty acid and incident atrial fibrillation: the womenꞋs Health initiative. Am J Cardiol. 2010;105(6):844-8. DOI:10.1016/j.amjcard.2009.11.039.Samuel M, Nattel S. Fish Oil Supplements May Increase the Risk for Atrial Fibrillation. Whar Does This Mean? Circulation. 2021;144(25):1991-4. DOI:10.1161/CIRCULATIONAHA.121.057464.Samuel M, Nattel S. Fish Oil Supplements May Increase the Risk for Atrial Fibrillation. Whar Does This Mean? Circulation. 2021;144(25):1991-4. DOI:10.1161/CIRCULATIONAHA.121.057464.Siscovick DS, Barringer TA, Fretts AM, et al. Omega-3 Polyunsaturated Fatty Acid (Fish Oil) Supplementation and the Prevention of Clinical Cardiovascular Disease: A Science Advisory from the American Heart Association. Circulation. 2017;135(15):e867-e884. DOI:10.1161/CIR.0000000000000482.Siscovick DS, Barringer TA, Fretts AM, et al. Omega-3 Polyunsaturated Fatty Acid (Fish Oil) Supplementation and the Prevention of Clinical Cardiovascular Disease: A Science Advisory from the American Heart Association. Circulation. 2017;135(15):e867-e884. DOI:10.1161/CIR.0000000000000482.Российское кардиологическое общество. Хроническая сердечная недостаточность. Клинические рекомендации, 2020. Российский Кардиологический Журнал. 2020;25(11):4083. DOI:10.15829/1560-4071-2020-4083.Russian Society of Cardiology, 2020. Clinical practice guidelines for chronic heart failure. Rus-sian Society of Cardiology. 2020;25(11):43. (In Russ.) DOI:10.15829/1560-4071-2020-4083.Беленков Ю.Н., Мареев В.Ю., Арутюнов Г.П., и др. Согласованное мнение экспертов о роли этиловых эфиров w-3 полиненасыщенных жирных кислот 90% для лечения и профилактики ХСН. Журнал Сердечная Недостаточность. 2011;4(66):244-6.Belenkov YuN, Mareev VYu, Arutyunov GP, et al. The agreed opinion of experts on the role of ethyl esters of w-3 polyunsaturated fatty acids 90% for the treatment and prevention of CHF. Journal of Heart Failure; 2011:4(66):244-6 (In Russ.)Ghio S, Scelsi L, Latini R, et al. Effects of n-3 polyunsaturated fatty acids and of rosuvastatin on left ventricular function in chronic heart failure: a substudy of GISSI-HF trial. Eur J Heart Fail. 2010;12(12):1345-53. DOI:10.1093/eurjhf/hfq172.Ghio S, Scelsi L, Latini R, et al. Effects of n-3 polyunsaturated fatty acids and of rosuvastatin on left ventricular function in chronic heart failure: a substudy of GISSI-HF trial. Eur J Heart Fail. 2010;12(12):1345-53. DOI:10.1093/eurjhf/hfq172.Vamagishi K, Iso H, Date C, et al. Fish, omega-3 polyunsaturated fatty acids, and mortality from cardiovascular diseases in a nationwide community-based cohort of Japanese men and women the JACC Study. J Am Coll Cardiol. 2008;52(12):988-96. DOI:10.1016/j.jacc.2008.06.018.Vamagishi K, Iso H, Date C, et al. Fish, omega-3 polyunsaturated fatty acids, and mortality from cardiovascular diseases in a nationwide community-based cohort of Japanese men and women the JACC Study. J Am Coll Cardiol. 2008;52(12):988-96. DOI:10.1016/j.jacc.2008.06.018.Duda MK, O Shea KM, Lei B, et al. Dietary supplementation with omega-3 PUFA increases adiponectin and attenuates ventricular remodeling and dysfunction with pressure overload. Cardiovasc Res. 2007;76(2):303-10. DOI:10.1016/j.cardiores.2007.07.002.Duda MK, OꞋShea KM, Lei B, et al. Dietary supplementation with omega-3 PUFA increases adi-ponectin and attenuates ventricular remodeling and dysfunction with pressure overload. Cardiovasc Res. 2007;76(2):303-10. DOI:10.1016/j.cardiores.2007.07.002.Mehra MR, Lavie CJ, Ventura HO, Milani RV. Fish oils produce anti-inflammatory effects and improved body weight in severe heart failure. J Heart lung Transplant. 2006;25(7):834-38. DOI:10.1016/j.healun.2006.03.005Mehra MR, Lavie CJ, Ventura HO, Milani RV. Fish oils produce anti-inflammatory effects and improved body weight in severe heart failure. J Heart lung Transplant. 2006;25(7):834-38. DOI:10.1016/j.healun.2006.03.005Bersch-Ferreira AC, Sampaio GR, Gehringer MO, et al. Association between polyunsaturated fatty acids and inflammatory markers in patients in secondary prevention of cardiovascular disease. Nutrition. 2017;37:30-6. DOI:10.1016/j.nut.2016.12.006.Bersch-Ferreira AC, Sampaio GR, Gehringer MO, et al. Association between polyunsaturated fatty acids and inflammatory markers in patients in secondary prevention of cardiovascular disease. Nutrition. 2017;37:30-6. DOI:10.1016/j.nut.2016.12.006.Varqiu R, Littarru GP, Fraschini M, et al. Enhancement of shortening velocity, power, and acto-myosin crossbridge (CB) kinetics following long-term treatment with propionyl-L-carnitine, coen-zyme-Q10 and omega-3 fatty acids in BIO TO-2 cardiomyopathic Syrian hamsters papillary muscle. Biofactors. 2010;36(3):229-39. DOI:10.1002/biof.95Varqiu R, Littarru GP, Fraschini M, et al. Enhancement of shortening velocity, power, and acto-myosin crossbridge (CB) kinetics following long-term treatment with propionyl-L-carnitine, coen-zyme-Q10 and omega-3 fatty acids in BIO TO-2 cardiomyopathic Syrian hamsters papillary muscle. Biofactors. 2010;36(3):229-39. DOI:10.1002/biof.95Berg AH, Scherer PE. Adipose tissue, inflammation, and cardiovascular disеase. Circ Rec 2005;96(9):939-49. DOI:10.1161/01.RES.0000163635.62927.34.Berg AH, Scherer PE. Adipose tissue, inflammation, and cardiovascular disеase. Circ Rec 2005;96(9):939-49. DOI:10.1161/01.RES.0000163635.62927.34.Neschen S, Morino K, Rossbacker JC, et al. Fish oil regylates adiponectin secretion by a peroxi-some proliberator-activated reseptor-gamma-dependent mechanism in mice. Diabetes. 2006;55(4):924-28. DOI:10.2337/diabetes.55.04.06.db05-0985.Neschen S, Morino K, Rossbacker JC, et al. Fish oil regylates adiponectin secretion by a peroxi-some proliberator-activated reseptor-gamma-dependent mechanism in mice. Diabetes. 2006;55(4):924-28. DOI:10.2337/diabetes.55.04.06.db05-0985.Duda MK, O'Shea KM, Tintinu A, et al. Fish oil, but not flaxseed oil, decreases inflammation and prevents pressure overload-induced cardiac dysfunction. Cardiovasc Rec. 2009;81(2):319-27. DOI:10.1093/cvr/cvn310.Duda MK, O'Shea KM, Tintinu A, et al. Fish oil, but not flaxseed oil, decreases inflammation and prevents pressure overload-induced cardiac dysfunction. Cardiovasc Rec. 2009;81(2):319-27. DOI:10.1093/cvr/cvn310.Duda MK, O'Shea KM, Stanley WC. Omega-3 polyunsaturated fatty acid supplementation for the treatment of heart failure mechanisms and clinical potential. Cardiovasc Res. 2009;84(1):33-41. DOI:10.1093/cvr/cvp169.Duda MK, O'Shea KM, Stanley WC. Omega-3 polyunsaturated fatty acid supplementation for the treatment of heart failure mechanisms and clinical potential. Cardiovasc Res. 2009;84(1):33-41. DOI:10.1093/cvr/cvp169.Wang Q, Liang X, Wang L, et al. Effect of omega-3 fatty acids supplementation on endothelial function: a meta-analysis of randomized controlled trials. Atherosclerosis. 2012;221(2):536-43. DOI:10.10.16/j.atherosclerosis.2012.01.006.Wang Q, Liang X, Wang L, et al. Effect of omega-3 fatty acids supplementation on endothelial function: a meta-analysis of randomized controlled trials. Atherosclerosis. 2012;221(2):536-43. DOI:10.10.16/j.atherosclerosis.2012.01.006.

The authors declare that there are no conflicts of interest present.